Mr. Stephen Kilmer reports

PROFOUND MEDICAL TO RELEASE SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 6TH - CONFERENCE CALL TO FOLLOW

Profound Medical Corp. will release its second quarter 2026 financial results after the market close on Thursday, Aug. 6, 2026.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Second quarter 2026 results conference call details

Date:  Thursday, Aug. 6, 2026

Time:  4:30 p.m. ET

Live call registration:  Register on-line.

The call will also be broadcast live and archived on the company's website in the investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (magnetic resonance imaging) (iMRI) procedures. The company's flagship platform, Tulsa-Pro, enables MRI-guided, incision-free prostate ablation. Physicians use the Tulsa Procedure to see, ablate and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care -- from whole-gland to subtotal, hemi, multifocal and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumours and osteoid osteoma, as well as for common gynecologic conditions, including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay and faster recovery -- and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical's technologies are approved across major global markets. Tulsa-Pro is cleared by the U.S. Food and Drug Administration (FDA) in the United States for transurethral ultrasound ablation (Tulsa) of prostate tissue. In addition, Tulsa-Pro is cleared for use in various jurisdictions, including Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the United Arab Emirates. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy -- expanding access to precise, personalized and incision-free treatment options worldwide.